June 14 (Reuters) - GlaxoSmithKline PLC:
* GLAXOSMITHKLINE PLC - GSK AND ITEOS ANNOUNCE COLLABORATION FOR EOS-448
* GSK - EOS-448 IS CURRENTLY IN PHASE I FOR ADVANCED SOLID TUMOURS WITH A RANDOMISED PD-1 COMBINATION STUDY PLANNED FOR 2022
* GSK - ITEOS TO RECEIVE A $625 MILLION UPFRONT PAYMENT IN ADDITION TO POTENTIAL MILESTONES, AND ROYALTY PAYMENTS ON EX-US SALES
* GSK -
* GSK - GSK AND ITEOS WILL CO-COMMERCIALISE AND SHARE PROFITS IN US
* GSK - GSK NOW HAS LEADING PORTFOLIO OF ANTIBODIES TARGETING CD226 AXIS - A KEY TARGET FOR NEXT-GENERATION IMMUNO-ONCOLOGY THERAPIES
* GSK - WITH THIS COLLABORATION GSK IS UNIQUELY POSITIONED WITH ACCESS TO ANTIBODIES THAT SYNERGISTICALLY TARGET ALL THREE KNOWN CD226 CHECKPOINTS
* GSK - ITEOS WILL BE ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $1.45 BILLION IN MILESTONE PAYMENTS, SHOULD EOS-448 PROGRAMME ACHIEVE CERTAIN MILESTONES
* GSK - WITHIN COLLABORATION, GSK AND ITEOS WILL SHARE RESPONSIBILITY AND COSTS FOR GLOBAL DEVELOPMENT OF EOS-448
* GSK - EXPECTS TO SUBMIT AN INVESTIGATIONAL NEW DRUG APPLICATION FOR GSK'562 (ANTI-PVRIG IN-LICENSED AS SRF-813 FROM SURFACE ONCOLOGY) BY MID-2022
* GSK - GSK AND ITEOS PLAN TO START COMBINATION STUDIES OF EOS-448 WITH DOSTARLIMAB IN 2022 Source text for Eikon: Further company coverage: